IP Library Granted Patent US 7,595,048
Granted Patent B2
US 7,595,048 · App. 10/519,925 · Granted Sep 29, 2009

Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1

Assignee: Ono Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,595,048
App. No.
10/519,925
Granted
Sep 29, 2009
Kind
B2
Abstract

Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of the immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibit the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.

Claims (4)

1. A method for treatment of cancer, wherein a pharmaceutically effective amount of completely human anti-PD-1 antibody is parenterally administered to a subject with cancer in which PD-L1 or PD-L2 is over-expressed, postoperatively.

2. The method for treatment of cancer according to claim 1 , which suppresses cancer metastasis.

3. A method for enhancing cytotoxic T cell activity toward PD-L1 or PD-L2 over-expressing cancer cells, which comprises administering a pharmaceutically effective amount of a completely human anti-PD-1 antibody to a subject with cancer in which PD-L1 or PD-L2 is over-expressed, wherein the effective dose of the completely human anti-PD-1 antibody is administered parenterally and postoperatively.

4. The method of claim 3 , whereby cancer metastasis is suppressed.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2019
From: FREEMAN, GORDON J.
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 050035/0042 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2005
From: HONJO, TASUKU; MINATO, NAGAHIRO; IWAI, YOSHIKO; SHIBAYAMA, SHIRO
To: ONO PHARMACEUTICAL CO., LTD.; HONJO, TASUKU
Reel/Frame 016887/0791 →
Priority Claims (2)
JP 2002-194491 · Jul 3, 2002 · national
JP 2003-029846 · Feb 6, 2003 · national
Continuity (1)
Related Publication 20060110383A1 · May 25, 2006